PeptideStack

MOTS-c

Discover the science behind MOTS-c, a mitochondrial-derived peptide and exercise mimetic. Explore MOTS-c benefits for metabolic health and weight loss.

Last updated:

Administration
subcutaneous
Origin
Mitochondrial Peptide

Overview

MOTS-c is a naturally occurring mitochondrial-derived peptide that functions as an exercise mimetic to regulate metabolic homeostasis. This peptide primarily targets skeletal muscle to enhance glucose metabolism, improve insulin sensitivity, and promote fatty acid oxidation. By activating cellular energy pathways, MOTS-c benefits individuals seeking targeted weight loss and improved physical performance. Research indicates its potential to combat age-related metabolic decline and obesity without requiring physical exertion.

Potential Benefits

  • Metabolic Homeostasis: MOTS-c significantly improves insulin sensitivity and reduces obesity by targeting skeletal muscle metabolism Lee et al., 2015.
  • Muscle Preservation: The peptide reduces myostatin expression and attenuates muscle atrophy signaling pathways Kumagai et al., 2021.
  • Glycemic Control: Clinical and preclinical data show it relieves hyperglycemia and improves insulin resistance, particularly in gestational diabetes models Yin et al., 2022.
  • Bone Metabolism Regulation: Emerging research highlights the role of MOTS-c in regulating bone metabolism and potentially preventing osteoporosis Yi et al., 2023.
  • Antiviral Properties: MOTS-c contributes to mitochondrial remodeling, demonstrating novel antiviral functions during infections like HBV Lin et al., 2024.
  • Cellular Protection: The peptide exhibits protective effects against pulmonary fibrosis and certain cellular dysfunctions Zhang et al., 2023.

Where to Buy MOTS-c

Pinnacle Peptide Labs

View →

Ascension Peptides

View →

Licensed Peptides

View →

These vendors are listed for research reference only. PeptideStack does not endorse, verify, or receive compensation from any vendor. Always verify purity and legitimacy independently.

Side Effects

Common side effects:

  • Injection site redness or irritation
  • Mild fatigue during initial use
  • Temporary flushing or warmth
  • Slight nausea

Rare or serious side effects:

  • Hypoglycemia in individuals on diabetes medication
  • Unintended weight loss
  • Unknown long-term mitochondrial alterations

MOTS-c is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.

Mechanism of Action

Cellular energy regulation begins when MOTS-c translocates to the nucleus to regulate gene expression in response to metabolic stress Benayoun et al., 2019. The peptide activates AMP-activated protein kinase (AMPK), a primary cellular energy sensor, which subsequently increases glucose uptake and fatty acid oxidation in skeletal muscle. This AMPK activation mimics the physiological effects of exercise, bypassing the need for physical exertion to achieve metabolic improvements Lee et al., 2015.

Systemic metabolic signaling occurs as MOTS-c circulates through the bloodstream, acting as an endocrine factor to communicate between mitochondria and the nucleus. By inhibiting the folate cycle and reducing de novo purine biosynthesis, it functionally prevents metabolic disorders and enhances cellular resilience Gao et al., 2023. Furthermore, MOTS-c suppresses disease progression in specific cancers by attenuating targeted protein deubiquitination Yin et al., 2024.

Origin & History

Mitochondrial discovery marked a paradigm shift in genetics when researchers identified MOTS-c as a peptide encoded directly by the mitochondrial genome rather than nuclear DNA. First detailed in 2015, it was recognized for its unique ability to promote metabolic homeostasis and reduce diet-induced obesity Lee et al., 2015. This discovery established mitochondria not just as cellular powerhouses, but as active signaling organelles capable of endocrine function.

Clinical development is currently advancing, with the MOTS-c peptide being investigated in human trials for improving insulin sensitivity in adults with prediabetes and obesity ClinicalTrials.gov, NCT07505745. Despite promising therapeutic exploitation Zheng et al., 2023, MOTS-c remains strictly designated for research purposes and has not yet received FDA approval for medical use.

Frequently Asked Questions

Research & Resources

PubMed Studies

View all studies on PubMed →

Clinical Trials

Data last updated: April 3, 2026

Related Peptides